Johanna Bendell
约翰娜·本德尔
MD
Chief Development Officer; Global Director of GI Cancer Research首席开发官；消化系统肿瘤研究全球总监
👥Biography 个人简介
Dr. Johanna Bendell is a leading GI oncology drug developer at Sarah Cannon Research Institute. She has led hundreds of early-phase oncology trials, pioneering novel combinations in colorectal, gastric, and pancreatic cancers that have advanced to registration-enabling studies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Early-Phase GI Oncology Drug Development
Designed and led first-in-human and phase I/II studies of targeted agents and immunotherapy combinations that defined the development path for multiple approved drugs.
BRAF/MEK Inhibition in Colorectal Cancer
Contributed key early trial data establishing BRAF-targeted combinations as effective therapy for BRAF V600E-mutated colorectal cancer.
Representative Works 代表性著作
Atezolizumab in combination with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer
Lancet Oncology (2019)
Reported IMblaze370 results defining the role of atezolizumab combinations in unselected metastatic colorectal cancer.
Phase I/II study of copanlisib plus cetuximab in metastatic colorectal cancer
Journal of Clinical Oncology (2021)
Explored PI3K inhibition with EGFR blockade, informing rational combination strategies for RAS wild-type colorectal cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
John Marshall
Georgetown University / Lombardi Comprehensive Cancer Center
关注 约翰娜·本德尔 的研究动态
Follow Johanna Bendell's research updates
留下邮箱，当我们发布与 Johanna Bendell（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment